Clinical trials: Large B-Cell Diffuse Lymphoma
DLBCL - Diffuse Large B Cell Lymphoma, Lymphoma
Real-World Study of DLBCL With Different Genetic Subtypes
To collect and evaluate the data of real-world treatment regimen, efficacy, safety and survival information of DLBCL patients with different genetic suptypes
- Trial name
- NCT06026488
- Testing
- Other
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Ruijin Hospital
Relapsed/refractory Diffuse Large B Cell Lymphoma
GPL in Patients with Relapsed/refractory Diffuse Large B Cell Lymphoma
Prospective, open-ended, single-arm, multicenter Phase II clinical trial. To evaluate the efficacy of Glofitamab, Poseltinib, and Lenalidomide combination therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.
- Trial name
- NCT05335018
- Testing
- Glofitamab, Poseltinib, Lenalidomide
- Where
- South Korea
- Volunteers
- 76 people
- Sponsor
- Seoul National University Hospital
Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL)
The Microbiome in Blood Cancer and HLH
The bacteria and viruses in the bowel (gut microbiota; GM) have powerful effects on the immune system. GM changes are seen in patients with auto-immune diseases, where the immune system attacks normal tissues, and cancer, and for…
- Conditions
- Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Haemophagocytic Lymphohistiocytosis
- Trial name
- NCT06734624
- Where
- United Kingdom
- Volunteers
- 750 people
- Sponsor
- University of Nottingham
Diffuse Large B Cell Lymphoma
Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2
The ImbruVeRCHOP-Trials is an Investigator-initiated, single-arm, multi-center, prospective, open phase I/II trial to evaluate the efficacy and feasibility of Ibrutinib and Bortezomib in the therapy of higher-risk DLBCL patients…
- Trial name
- ImbruVeRCHOP (NCT03129828)
- Testing
- Ibrutinib and Bortezomib + R-CHOP
- Where
- Germany
- Volunteers
- 38 people
- Sponsor
- Prof. Dr. Clemens Schmitt
Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL
This Phase 1a/1b study will evaluate the safety, tolerability and the pharmacokinetics/ pharmacodynamics (PK/ PD) of KT-413 in patients with R/R NHL.
- Conditions
- Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, DLBCL, MYD88 Gene Mutation
- Trial name
- NCT05233033
- Testing
- KT-413
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 7 people
- Sponsor
- Kymera Therapeutics, Inc.
Diffuse Large B Cell Lymphoma
RadiothErapy priMIng for CAR-T
The REMIT trial will investigate radiotherapy as a preferred bridging method prior to Tisagenlecleucel infusion in patients with relapsed or refractory Diffuse Large B Cell Lymphoma
- Trial name
- REMIT (NCT04726787)
- Testing
- Bridging Radiotherapy
- Where
- 3 sites in United Kingdom
- Volunteers
- 6 people
- Sponsor
- University College, London
Relapsed/Refractory Aggressive B-Cell Malignancies
A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies
This is a Phase 1/2 study to investigate the safety and efficacy of the CAR-T therapy, ONCT-808, in patients with relapsed/refractory (R/R) aggressive B cell malignancies.
- Trial name
- NCT05588440
- Testing
- ONCT-808, Bridging Therapy
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- Oncternal Therapeutics, Inc
B-cell Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia
Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies
The purpose of this study is to determine the safety and tolerability of intravenous (IV) and subcutaneous (SC) administration of XmAb13676 and to determine the maximally tolerated dose (MTD) and/or recommended dose (RD).
- Trial name
- NCT02924402
- Testing
- XmAb13676
- Where
- 23 sites in United States, France and 2 more
- Volunteers
- 154 people
- Sponsor
- Xencor, Inc.
Lymphoma, Large B-Cell, Diffuse
Optimizing Lymphodepletion to Improve Outcomes in Patients Receiving Cell Therapy With Kymriah
This is a Phase 1b study of participants with Diffuse Large B Cell Lymphoma (DLBCL). The purpose of this study is to identify an optimized lymphodepletion (LD) regimen by evaluating standard and intermediate doses of Fludarabine…
- Trial name
- LOKI (NCT06003179)
- Testing
- Cyclophosphamide, TLI, Fludarabine
- Where
- Canada
- Sponsor
- University Health Network, Toronto
Newly Diagnosed Diffuse Large B-cell Lymphoma
A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma
A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with newly Diagnosed Diffuse Large B-cell Lymphoma
- Trial name
- NCT06683885
- Testing
- Obutinib or Decitabine, Rituximab, Compound Cyclophosphamide Tablets and Prednisone
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Mingzhi Zhang
Diffuse Large B Cell Lymphoma
Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission
This single-arm, prospective clinical study will evaluate the efficacy and safety of Zanubrutinib-based maintenance therapy for post-remission in newly diagnosed DLBCL who are intolerant to first-line intensive chemotherapy.
- Trial name
- NCT06669143
- Testing
- Zanubrutinib, Lenalidomide
- Volunteers
- 19 people
- Sponsor
- Ruijin Hospital
Large B-Cell Diffuse Lymphoma
Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma
The purpose of this study is to determine the safety and tolerability of adding oral azacitidine to the chemotherapy combination R-ICE. This study will also look at whether or not disease outcomes improve with the combination.
- Trial name
- NCT03450343
- Testing
- Oral azacitidine, R-ICE
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Medical University of South Carolina
Diffuse Large B-cell Lymphoma
Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma
Screening (up to 28 days); daily treatment until disease progression, unacceptable toxicity or death, withdrawal of consent, lost to follow-up, or study termination from sponsor; treatment (up to 2 years), safety follow-up (30…
- Trial name
- NCT03145064
- Testing
- Zanubrutinib
- Where
- 11 sites in China
- Volunteers
- 41 people
- Sponsor
- BeiGene
Marginal Zone Lymphoma, Follicular Lymphoma
BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)
This was a multicenter, open-label, phase 2 study to evaluate efficacy, safety, and tolerability of BGB-3111 (zanubrutinib) 160 milligrams (mg) twice daily (BID) in combination with rituximab in Chinese participants with…
- Conditions
- Marginal Zone Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma
- Trial name
- NCT03520920
- Testing
- Zanubrutinib, Rituximab
- Where
- 4 sites in China
- Volunteers
- 41 people
- Sponsor
- BeiGene
Diffuse Large B-cell Lymphoma, Follicular Lymphoma
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
The drug that will be investigated in the study is an antibody, GEN3009. Since this is the first study of GEN3009 in humans, the main purpose is to evaluate safety.
- Conditions
- Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma
- Trial name
- NCT04358458
- Testing
- GEN3009, Epcoritamab
- Where
- 17 sites in United States, Belgium and 3 more
- Volunteers
- 46 people
- Sponsor
- Genmab
Diffuse Large B Cell Lymphoma (DLBCL)
The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study
The purpose of this study is to evaluate the the efficacy and safety in the real-world settings of glofitamab among Chinese R/R DLBCL participants.
- Trial name
- NCT06656234
- Testing
- Glofitamab, Obinutuzumab
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Ruijin Hospital
Diffuse Large B Cell Lymphoma
Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma
A single-center, open, single-arm clinical study of the efficacy and safety of a novel targeted agent in combination with R-ICE in the treatment of relapsed and refractory diffuse Large B-cell lymphoma.
- Trial name
- R-ICE+X (NCT05348213)
- Testing
- Zanubrutinib plus R-ICE, Decitabine plus R-ICE, Chidamide plus R-ICE
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Ruijin Hospital
Diffuse Large B Cell Lymphoma
Autologous Hematopoietic Stem Cell Boost Study After CAR-T Therapy
This is a prospective, single-arm, open study to observe the efficacy and safety of the CART-SCB regimen (Clinical Regimen for the Prospective Study of Autologous Hematopoietic Stem Cell Boost for the Improvement of Bone Marrow…
- Trial name
- NCT06589089
- Testing
- autologous hematopoietic stem cell
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Ruijin Hospital
Diffuse Large B Cell Lymphoma (DLBCL)
Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial）
This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of orelabrutinib combined with the R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone) regimen…
- Trial name
- NCT06647940
- Testing
- Orelabrutinib Oral Tablet, R-CHOP Protocol
- Where
- 11 sites in China
- Volunteers
- 39 people
- Sponsor
- Sun Yat-sen University
Diffuse Large B Cell Lymphoma
Selinexor Combined With BEAM for ASCT in R/R DLBCL With MYC Positive
To evaluate the efficacy and safety of selinexor combined with BEAM pretreatment regimen in ASCT of recurrent and refractory DLBCL patients with immunohistochemical positive for MYC
- Trial name
- NCT06652139
- Testing
- selinexor combined with BEAM regimen, BEAM regimen
- Volunteers
- 82 people
- Sponsor
- Ruijin Hospital